IP Library Granted Patent US 8,371,296
Granted Patent B2
US 8,371,296 · App. 11/382,116 · Granted Feb 12, 2013

Method and apparatus for nitric oxide generation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,371,296
App. No.
11/382,116
Granted
Feb 12, 2013
Kind
B2
Abstract

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. Precise delivery of nitric oxide at therapeutic levels of 20 to 100 ppm and inhibition of reaction of nitric oxide with oxygen to form toxic impurities such as nitrogen dioxide can provide effective inhalation therapy for pulmonary hypertension.

Claims (12)

1. An apparatus for delivering a therapeutic gas including nitric oxide comprising:

a receptacle including a non-electrolytic nitric oxide precursor receiver;

the non-electrolytic nitric oxide precursor receiver including a transport gas inlet and a therapeutic gas outlet; and

the transport gas inlet fluidly communicating from a source of a transport gas to the therapeutic gas outlet through the non-electrolytic nitric oxide precursor receiver,

wherein the transport gas inlet includes a gas distributor in the non-electrolytic nitric oxide precursor receiver.

2. The apparatus of claim 1 wherein the non-electrolytic nitric oxide precursor receiver is configured to receive a non-electrolytic nitric oxide precursor that includes a precursor salt.

3. The apparatus of claim 1 further including a therapeutic gas delivery system fluidly connectable to the therapeutic gas outlet.

4. The apparatus of claim 3 wherein the therapeutic gas delivery system includes a therapeutic gas purifier.

5. The apparatus of claim 4 wherein the therapeutic gas purifier includes a filter.

6. The apparatus of claim 3 wherein the therapeutic gas delivery system includes a mask fluidly connectable to the therapeutic gas outlet.

7. The apparatus of claim 6 wherein the mask is connectable to a mammal.

8. The apparatus of claim 1 wherein the source of the transport gas includes a gas flow controller.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
SECURITY INTEREST Recorded Mar 16, 2026
From: VERO BIOTECH INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT
Reel/Frame 075117/0935 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 3, 2024
From: RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.)
To: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC)
Reel/Frame 066186/0611 →
CHANGE OF NAME Recorded Feb 14, 2022
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 059085/0418 →
SECURITY INTEREST Recorded Dec 29, 2020
From: VERO BIOTECH LLC
To: RUNWAY GROWTH CREDIT FUND INC.
Reel/Frame 054866/0589 →
CHANGE OF NAME Recorded Aug 7, 2018
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 048173/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2013
From: FINE, DAVID H.; MACDONALD, STEPHEN J.; ROUNBEHLER, DAVID; WHEELER, DAVID; ROLFE, JONATHAN L.; JARVIS, GEORGE
To: GENO LLC
Reel/Frame 029586/0923 →